Ahmet Emin ERBAYCU, Mine GAYAF, Işıl KARASU, Süleyman Emrah ORAY, Dilek KALENCİ, Ayşe ÖZSÖZ, Nimet AKSEL

Küçük hücreli dışı akciğer kanserinde serum karsino embriyonik antijen düzeyinin hastalık özellikleri ile ilişkisi

Serum karsino embriyonik antijen (CEA) akciğer kanserinin bazı parametreleriyle ilişkilidir. Çalışmada bu belirtecin küçük hücreli dışı akciğer karsinomu (KHDAK)'deki tanısal değerini ve tümör özellikleriyle ilişkisini araştırdık.Eylül 2007 ile Eylül 2008 tarihleri arasında KHDAK tanısı konulan ve tedavi edilmemiş 101 hastanın serum karsinoembriyojenik antijen düzeylerine bakıldı.Hastaların yaş ortalaması 63.1±10.2 yıl idi. Hastaların 91'i erkek, 10'u kadındı. Epidermoid karsinom %58.9, adenokarsinom %22.4, alt tipi belirlenemeyen %18.7 idi. Evre I %15.8, Evre II %11.9, Evre III %32.7 ve Evre IV %39.6 idi. Hasta grubunda serum CEA seviyeleri sağlıklı kontrol grubuna göre daha yüksek idi (p0.05). Serum CEA düzeyi ile radyolojik T1, T2, T3 ve T4 arasında ve radyolojik N0, N1, N2 ve N3 arasında anlamlı ilişki bulunmadı (p>0.05). Serum CEA düzeyi M1 ve M0 hastalarda benzer idi (p>0.05).Karaciğer metastazı olan hastalarda serum CEA düzeyi karaciğer metastazı olmayan hastalara göre yüksek idi (p

The relatıon of serum carcınoembrıonıc antıgen level wıth the dısease characterıstıcs of non-small cell lung cancer

Serum carcino embrionic antigen (CEA) is related with some parameters of lung cancer. In the study, we searched the diagnostic yield and the relation with tumor characteristics in nonsmall cell lung cancer (NSCLC).The serum level of CEA was assessed in 101 patients diagnosed NSCLC between September 2007 and September 2008 before any treatment.The avarage age was 63.1±10,2 years. There were 91 men and 10 women. There was epidermoid carcinoma in 58.9%, adenocarcinoma in 22.4% and tumor without subtype in 18.7%. There was stage I in 15.8%, stage II in 11.9%, stage III in 32.7% and stage IV in 39.6%. The serum CEA level was higher in patient group than the healthy subjects (p0.05). There were also no relation between serum CEA and radiological T1, T2, T3, T4 and radiological N0, N1, N2, N3 (p>0.05). The serum CEA was similar in patients with M0 and M1 (p>0,05). The serum CEA was higher in patients with liver metastasis than those without liver metastasis (p

PDF

___

1. Butch AW & Pappas AA. Tumor markers. In; Tretz Textbook of Clinical Biochomistry 2.Edition. Eds. Burtis CA & Ashwood ER, Saunders Company, USA, 1994; pp: 483- 500.
2. Uzaslan EK, Özyard›mc› N, Konuk S, Karaca fi, Karada¤ M, Gözü RO, Yüksel EG, Alkan B. Akci¤er kanserinin tan› ve tiplendirilmesinde tümör belirleyicilerinin yeri. Bursa Devlet Hastanesi Bülteni 1999; 15: 69-74.
3. Gold P, Shuter D, Freedman SO. Carcino- embriyonic antigen in clinical medicine. Cancer 1978; 42: 1399-405.
4. Taş F, Aydıner A, Topuz E, Yasasever V, Karadeniz A, Saip P. Utility of the serum tumor markers: CYFRA 21-1, CEA and squamous cell carcinoma antigen (SCC) in squamous cell cancer. J Exp Clin Cancer Res 2000; 19: 477-81.
5. Gediz R. Bronş Kanseri olgular›nda tümör markerlarının tanı değerleri. Uzmanl›k Tezi, Bursa, 1996: s 36-4
6. Pina TC, Zapata IT, Hernandez FC, López JB, Paricio PP, Hernández PM. Tumor markers in serum, BAL and biopsy in lung carcinoma : what environment lends the optimum diagnostic yield? Clinica Chimica Acta 2001; 30 s: 27-34.
7. Salgia R, Harpole D, Herndon JE, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res 2001; 21: 1241-6.
8. Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2004; 10: 76-80.
9. Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Onitsuka T. Prognostic determinants for lung cancer patients with preoperative high CEA. Thorac Cardiovasc Surg 2005; 53: 300-4.
10. Nonaka M, Kataoka D, Yamamoto S, et al. Pre- and post-operative serum carcinoembryonic antigen in primary lung adenocarcinoma. Ann Thorac Cardiovasc Surg 2004; 10: 281-4.
11. Takamochi K, Yoshida J, Nishimura M, Yokose T, Sasaki S, Nishiwaki Y, Suzuki K, Nagai K. Prognosis and histologic features of small pulmonary adenocarcinoma based on serum carcinoembryonic antigen level and computed tomographic findings. Eur J Cardio-Thorac Surg 2004; 25: 877-83.
12. Ando S, Kimura H, Iwai N, Kakizawa K, Shima M, Ando M. The significance of tumour markers as an indication for mediastinoscopy in non- small cell lung cancer. Respirology 2003; 8: 163-7.
13. Watanabe K, Nomori H, Ohtsuka T, Naruke T, Uno K. False negative cases of (FDG-PET) imaging in small cell lung cancer less than 3 cm in size. Nihon Kokyuki Gakkai Zasshi 2004; 42: 787-93.
14. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Serum carcinoembryonic antigen level and pleural lavage cytology in woman with non-small cell lung cancer. Thorac Cardiovasc Surg 2008; 56: 422-5.
15. Trapé J, Buxo J, Pérez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003; 23: 4277-81.
16. Matsuoka K, Sumitomo S, Nakashima N, Nakajima D, Misaki N. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32: 435-9.
17. Shoji F, Yoshino I, Yano T, Kometani T, Ohba T, Kouso H, Takenaka T, Miura N, Okazaki H, Maehara Y. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer 2007; 110: 2793-8.